Head-to-head · WeighScore
Pallas Health vs RxSpan MD
By GLP-1 ScorecardUpdated
Score comparison
RxSpan MD has the higher recorded score — 84.3/100 to 69.3/100.
RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.
Before you choose
RxSpan MD does not publish a semaglutide price, so its RxSpan MD review sets out what it does disclose, while the Pallas Health review explains the conditions attached to Pallas Health's figure. The semaglutide cost page compares published rates across the field. Ask RxSpan MD for a written total before treating either one as the cheaper choice.
If neither one fits, Pallas Health vs Synergy Rx and Peptivo vs RxSpan MD compare each of them with another graded program, and the list of alternatives to Pallas Health ranks the programs closest to Pallas Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Pallas Health | RxSpan MD |
|---|---|---|
| WeighScore | 69.3/100 | 84.3/100 |
| Grade | C | B |
| Site position | #142 | #4 |
| Semaglutide | $139 first period, then $199 every four weeks (compounded; confirm selected quote) | Current compounded quote unconfirmed |
| Tirzepatide | $179 first period, then $299 every four weeks (compounded; confirm selected quote) | Current compounded quote unconfirmed |
| Coverage | Confirm treatment and visit requirements for your state | Confirm treatment availability during intake |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Publishes first-period and four-week renewal amounts
- Explains when the charge is triggered and how to cancel future renewal
- Terms link to a pharmacy partner directory
What to consider
- Annual monthly equivalents do not establish the selected debit
- Once prescribed, the current cycle ordinarily is not prorated or refunded
- The six-month promise has separate eligibility and timing requirements
Site position #4 · B
Strengths
- Current public catalog lists Ozempic, Wegovy, Mounjaro and Zepbound
- Public terms describe independent healthcare providers
- Homepage describes messaging and care-team appointments
What to consider
- Homepage advertises compounded plans that the current catalog did not substantiate
- Current oral GLP-1 availability is unconfirmed
- Prior compounded prices are not a current quote; selected dose, supply, pharmacy and fee inclusions need confirmation
- Public terms do not establish unused prepaid-treatment refund amounts
Featured provider
RxSpan MD
RxSpan MD scores 84.3/100 (B). RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.